The phase 2 DIMENSION study results showed that SAGE-71 was well-tolerated but did not meet its primary end point, leading to Sage Therapeutics’ decision to discontinue its development.:
Source: Neurology Read More
Huntington Agent SAGE-718 to be Discontinued Following Disappointing Phase 2 DIMENSION Trial Results
Related Posts
<![CDATA[Novel Digital Measures for Tracking Disease
Progression in Duchenne Muscular Dystrophy Beyond Loss of
Ambulation]]>
<![CDATA[Novel Digital Measures for Tracking Disease Progression in Duchenne Muscular Dystrophy Beyond Loss of Ambulation]]>
